Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 635

1.

Addition of cyclophosphamide on insufficient response to pomalidomide and dexamethasone: results of the phase II PERSPECTIVE Multiple Myeloma trial.

Weisel KC, Scheid C, Zago M, Besemer B, Mai EK, Haenel M, Duerig J, Munder M, Lindemann HW, Seckinger A, Kunz C, Benner A, Hose D, Jauch A, Salwender H, Goldschmidt H.

Blood Cancer J. 2019 Apr 8;9(4):45. doi: 10.1038/s41408-019-0206-8. No abstract available.

2.

Randomized, Double-blind, Placebo-controlled, Multicenter Study of Siltuximab in High-risk Smoldering Multiple Myeloma.

Brighton TA, Khot A, Harrison SJ, Ghez D, Weiss BM, Kirsch A, Magen H, Gironella M, Oriol A, Streetly M, Kranenburg B, Qin X, Bandekhar R, Hu P, Guilfoyle M, Qi M, Nemat S, Goldschmidt H.

Clin Cancer Res. 2019 Mar 19. pii: clincanres.3470.2018. doi: 10.1158/1078-0432.CCR-18-3470. [Epub ahead of print]

PMID:
30890552
3.

[Erratum to: First-line treatment of multiple myeloma].

Breitkreutz I, Raab M, Goldschmidt H.

Internist (Berl). 2019 Mar 18. doi: 10.1007/s00108-019-0581-z. [Epub ahead of print] German. No abstract available.

PMID:
30887073
4.

Genome-wide interaction and pathway-based identification of key regulators in multiple myeloma.

Chattopadhyay S, Thomsen H, Yadav P, da Silva Filho MI, Weinhold N, Nöthen MM, Hoffman P, Bertsch U, Huhn S, Morgan GJ, Goldschmidt H, Houlston R, Hemminki K, Försti A.

Commun Biol. 2019 Mar 4;2:89. doi: 10.1038/s42003-019-0329-2. eCollection 2019.

5.

Quantitative dynamic 18F-FDG PET/CT before autologous stem cell transplantation predicts survival in multiple myeloma.

Sachpekidis C, Merz M, Kopp-Schneider A, Jauch A, Raab MS, Sauer S, Hillengass J, Goldschmidt H, Dimitrakopoulou-Strauss A.

Haematologica. 2019 Feb 14. pii: haematol.2018.213041. doi: 10.3324/haematol.2018.213041. [Epub ahead of print]

6.

Genome-wide association study of monoclonal gammopathy of unknown significance (MGUS): comparison with multiple myeloma.

Thomsen H, Chattopadhyay S, Weinhold N, Vodicka P, Vodickova L, Hoffmann P, Nöthen MM, Jöckel KH, Langer C, Hajek R, Hallmans G, Pettersson-Kymmer U, Ohlsson C, Späth F, Houlston R, Goldschmidt H, Hemminki K, Försti A.

Leukemia. 2019 Feb 8. doi: 10.1038/s41375-019-0396-x. [Epub ahead of print] No abstract available.

PMID:
30737484
7.

Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension.

Bringhen S, Milan A, D'Agostino M, Ferri C, Wäsch R, Gay F, Larocca A, Offidani M, Zweegman S, Terpos E, Goldschmidt H, Cavo M, Ludwig H, Driessen C, Auner HW, Caers J, Gramatzki M, Dimopoulos MA, Boccadoro M, Einsele H, Sonneveld P, Engelhardt M.

J Intern Med. 2019 Feb 6. doi: 10.1111/joim.12882. [Epub ahead of print]

PMID:
30725503
8.

Do we need cytogenetics in the follow-up of multiple myeloma?

Gay F, Goldschmidt H.

Br J Haematol. 2019 May;185(3):399-401. doi: 10.1111/bjh.15781. Epub 2019 Feb 1. No abstract available.

PMID:
30706441
9.

Cereblon-binding proteins expression levels correlate with hyperdiploidy in newly diagnosed multiple myeloma patients.

Kriegsmann K, Baertsch MA, Awwad MHS, Merz M, Hose D, Seckinger A, Jauch A, Becker N, Benner A, Raab MS, Hillengass J, Bertsch U, Dürig J, Salwender HJ, Hänel M, Fenk R, Munder M, Weisel K, Müller-Tidow C, Goldschmidt H, Hundemer M.

Blood Cancer J. 2019 Jan 29;9(2):13. doi: 10.1038/s41408-019-0174-z.

10.

High subclonal fraction of 17p deletion is associated with poor prognosis in multiple myeloma.

Thakurta A, Ortiz M, Blecua P, Towfic F, Corre J, Serbina NV, Flynt E, Yu Z, Yang Z, Palumbo A, Dimopoulos MA, Gutierrez NC, Goldschmidt H, Sonneveld P, Avet-Loiseau H.

Blood. 2019 Mar 14;133(11):1217-1221. doi: 10.1182/blood-2018-10-880831. Epub 2019 Jan 28.

11.

Patients with precursor disease exhibit similar psychological distress and mental HRQOL as patients with active myeloma.

Maatouk I, He S, Hummel M, Hemmer S, Hillengass M, Goldschmidt H, Hartmann M, Herzog W, Hillengass J.

Blood Cancer J. 2019 Jan 21;9(2):9. doi: 10.1038/s41408-019-0172-1. No abstract available.

12.

Genetic polymorphisms in genes of class switch recombination and multiple myeloma risk and survival: an IMMEnSE study.

Campa D, Martino A, Macauda A, Dudziński M, Suska A, Druzd-Sitek A, Raab MS, Moreno V, Huhn S, Butrym A, Sainz J, Szombath G, Rymko M, Marques H, Lesueur F, Vangsted AJ, Vogel U, Kruszewski M, Subocz E, Buda G, Iskierka-Jażdżewska E, Ríos R, Merz M, Schöttker B, Mazur G, Perrial E, Martinez-Lopez J, Butterbach K, García Sanz R, Goldschmidt H, Brenner H, Jamroziak K, Reis RM, Kadar K, Dumontet C, Wątek M, Haastrup EK, Helbig G, Jurczyszyn A, Jerez A, Varkonyi J, Barington T, Grzasko N, Zaucha JM, Andersen V, Zawirska D, Canzian F.

Leuk Lymphoma. 2019 Jan 11:1-9. doi: 10.1080/10428194.2018.1551536. [Epub ahead of print]

PMID:
30633655
13.

Author Correction: Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma.

Went M, Sud A, Försti A, Halvarsson BM, Weinhold N, Kimber S, van Duin M, Thorleifsson G, Holroyd A, Johnson DC, Li N, Orlando G, Law PJ, Ali M, Chen B, Mitchell JS, Gudbjartsson DF, Kuiper R, Stephens OW, Bertsch U, Broderick P, Campo C, Bandapalli OR, Einsele H, Gregory WA, Gullberg U, Hillengass J, Hoffmann P, Jackson GH, Jöckel KH, Johnsson E, Kristinsson SY, Mellqvist UH, Nahi H, Easton D, Pharoah P, Dunning A, Peto J, Canzian F, Swerdlow A, Eeles RA, Kote-Jarai Z, Muir K, Pashayan N; PRACTICAL consortium, Nickel J, Nöthen MM, Rafnar T, Ross FM, da Silva Filho MI, Thomsen H, Turesson I, Vangsted A, Andersen NF, Waage A, Walker BA, Wihlborg AK, Broyl A, Davies FE, Thorsteinsdottir U, Langer C, Hansson M, Goldschmidt H, Kaiser M, Sonneveld P, Stefansson K, Morgan GJ, Hemminki K, Nilsson B, Houlston RS.

Nat Commun. 2019 Jan 10;10(1):213. doi: 10.1038/s41467-018-08107-8.

14.

Genetic correlation between multiple myeloma and chronic lymphocytic leukaemia provides evidence for shared aetiology.

Went M, Sud A, Speedy H, Sunter NJ, Försti A, Law PJ, Johnson DC, Mirabella F, Holroyd A, Li N, Orlando G, Weinhold N, van Duin M, Chen B, Mitchell JS, Mansouri L, Juliusson G, Smedby KE, Jayne S, Majid A, Dearden C, Allsup DJ, Bailey JR, Pratt G, Pepper C, Fegan C, Rosenquist R, Kuiper R, Stephens OW, Bertsch U, Broderick P, Einsele H, Gregory WM, Hillengass J, Hoffmann P, Jackson GH, Jöckel KH, Nickel J, Nöthen MM, da Silva Filho MI, Thomsen H, Walker BA, Broyl A, Davies FE, Hansson M, Goldschmidt H, Dyer MJS, Kaiser M, Sonneveld P, Morgan GJ, Hemminki K, Nilsson B, Catovsky D, Allan JM, Houlston RS.

Blood Cancer J. 2018 Dec 21;9(1):1. doi: 10.1038/s41408-018-0162-8.

15.

[First-line treatment of multiple myeloma].

Breitkreutz I, Raab M, Goldschmidt H.

Internist (Berl). 2019 Jan;60(1):23-33. doi: 10.1007/s00108-018-0527-x. Review. German. Erratum in: Internist (Berl). 2019 Mar 18;:.

PMID:
30552458
16.

Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial.

Dimopoulos MA, Gay F, Schjesvold F, Beksac M, Hajek R, Weisel KC, Goldschmidt H, Maisnar V, Moreau P, Min CK, Pluta A, Chng WJ, Kaiser M, Zweegman S, Mateos MV, Spencer A, Iida S, Morgan G, Suryanarayan K, Teng Z, Skacel T, Palumbo A, Dash AB, Gupta N, Labotka R, Rajkumar SV; TOURMALINE-MM3 study group.

Lancet. 2019 Jan 19;393(10168):253-264. doi: 10.1016/S0140-6736(18)33003-4. Epub 2018 Dec 10.

PMID:
30545780
17.

Cell-based immunotherapy approaches for multiple myeloma.

Kriegsmann K, Kriegsmann M, Cremer M, Schmitt M, Dreger P, Goldschmidt H, Müller-Tidow C, Hundemer M.

Br J Cancer. 2019 Jan;120(1):38-44. doi: 10.1038/s41416-018-0346-9. Epub 2018 Dec 6. Review.

PMID:
30518815
18.

Navigating the treatment landscape in multiple myeloma: which combinations to use and when?

Goldschmidt H, Ashcroft J, Szabo Z, Garderet L.

Ann Hematol. 2019 Jan;98(1):1-18. doi: 10.1007/s00277-018-3546-8. Epub 2018 Nov 23. Review.

19.

Cytogenetic intraclonal heterogeneity of plasma cell dyscrasia in AL amyloidosis as compared with multiple myeloma.

Bochtler T, Merz M, Hielscher T, Granzow M, Hoffmann K, Krämer A, Raab MS, Hillengass J, Seckinger A, Kimmich C, Dittrich T, Müller-Tidow C, Hose D, Goldschmidt H, Hegenbart U, Jauch A, Schönland SO.

Blood Adv. 2018 Oct 23;2(20):2607-2618. doi: 10.1182/bloodadvances.2018023200.

20.

The prognostic and predictive value of IKZF1 and IKZF3 expression in T-cells in patients with multiple myeloma.

Awwad MHS, Kriegsmann K, Plaumann J, Benn M, Hillengass J, Raab MS, Bertsch U, Munder M, Weisel K, Salwender HJ, Hänel M, Fenk R, Dürig J, Müller-Tidow C, Goldschmidt H, Hundemer M.

Oncoimmunology. 2018 Aug 1;7(10):e1486356. doi: 10.1080/2162402X.2018.1486356. eCollection 2018.

PMID:
30288348
21.

PRC2 targeting is a therapeutic strategy for EZ score defined high-risk multiple myeloma patients and overcome resistance to IMiDs.

Herviou L, Kassambara A, Boireau S, Robert N, Requirand G, Müller-Tidow C, Vincent L, Seckinger A, Goldschmidt H, Cartron G, Hose D, Cavalli G, Moreaux J.

Clin Epigenetics. 2018 Oct 3;10(1):121. doi: 10.1186/s13148-018-0554-4.

22.

A multiple myeloma classification system that associates normal B-cell subset phenotypes with prognosis.

Bødker JS, Brøndum RF, Schmitz A, Schönherz AA, Jespersen DS, Sønderkær M, Vesteghem C, Due H, Nørgaard CH, Perez-Andres M, Samur MK, Davies F, Walker B, Pawlyn C, Kaiser M, Johnson D, Bertsch U, Broyl A, van Duin M, Shah R, Johansen P, Nørgaard MA, Samworth RJ, Sonneveld P, Goldschmidt H, Morgan GJ, Orfao A, Munshi N, Johnson HE, El-Galaly T, Dybkær K, Bøgsted M.

Blood Adv. 2018 Sep 25;2(18):2400-2411. doi: 10.1182/bloodadvances.2018018564. Erratum in: Blood Adv. 2019 Mar 26;3(6):874.

23.

Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma.

Went M, Sud A, Försti A, Halvarsson BM, Weinhold N, Kimber S, van Duin M, Thorleifsson G, Holroyd A, Johnson DC, Li N, Orlando G, Law PJ, Ali M, Chen B, Mitchell JS, Gudbjartsson DF, Kuiper R, Stephens OW, Bertsch U, Broderick P, Campo C, Bandapalli OR, Einsele H, Gregory WA, Gullberg U, Hillengass J, Hoffmann P, Jackson GH, Jöckel KH, Johnsson E, Kristinsson SY, Mellqvist UH, Nahi H, Easton D, Pharoah P, Dunning A, Peto J, Canzian F, Swerdlow A, Eeles RA, Kote-Jarai Z, Muir K, Pashayan N, Nickel J, Nöthen MM, Rafnar T, Ross FM, da Silva Filho MI, Thomsen H, Turesson I, Vangsted A, Andersen NF, Waage A, Walker BA, Wihlborg AK, Broyl A, Davies FE, Thorsteinsdottir U, Langer C, Hansson M, Goldschmidt H, Kaiser M, Sonneveld P, Stefansson K, Morgan GJ, Hemminki K, Nilsson B, Houlston RS; PRACTICAL consortium.

Nat Commun. 2018 Sep 13;9(1):3707. doi: 10.1038/s41467-018-04989-w. Erratum in: Nat Commun. 2019 Jan 10;10(1):213.

24.

European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when.

Caers J, Garderet L, Kortüm KM, O'Dwyer ME, van de Donk NWCJ, Binder M, Dold SM, Gay F, Corre J, Beguin Y, Ludwig H, Larocca A, Driessen C, Dimopoulos MA, Boccadoro M, Gramatzki M, Zweegman S, Einsele H, Cavo M, Goldschmidt H, Sonneveld P, Delforge M, Auner HW, Terpos E, Engelhardt M.

Haematologica. 2018 Nov;103(11):1772-1784. doi: 10.3324/haematol.2018.189159. Epub 2018 Aug 31.

25.

Enrichment of B cell receptor signaling and epidermal growth factor receptor pathways in monoclonal gammopathy of undetermined significance: a genome-wide genetic interaction study.

Chattopadhyay S, Thomsen H, da Silva Filho MI, Weinhold N, Hoffmann P, Nöthen MM, Marina A, Jöckel KH, Schmidt B, Pechlivanis S, Langer C, Goldschmidt H, Hemminki K, Försti A.

Mol Med. 2018 Jun 11;24(1):30. doi: 10.1186/s10020-018-0031-8.

26.

IL-10 inducible CD8+ regulatory T-cells are enriched in patients with multiple myeloma and impact the generation of antigen-specific T-cells.

Plaumann J, Engelhardt M, Awwad MHS, Echchannaoui H, Amman E, Raab MS, Hillengass J, Halama N, Neuber B, Müller-Tidow C, Goldschmidt H, Hundemer M.

Cancer Immunol Immunother. 2018 Nov;67(11):1695-1707. doi: 10.1007/s00262-018-2230-0. Epub 2018 Aug 20.

PMID:
30128739
27.

Chemotherapy-induced peripheral neuropathy: evidence from genome-wide association studies and replication within multiple myeloma patients.

Mahmoudpour SH, Bandapalli OR, da Silva Filho MI, Campo C, Hemminki K, Goldschmidt H, Merz M, Försti A.

BMC Cancer. 2018 Aug 15;18(1):820. doi: 10.1186/s12885-018-4728-4.

28.

Association of resilience with health-related quality of life and depression in multiple myeloma and its precursors: results of a German cross-sectional study.

Maatouk I, He S, Becker N, Hummel M, Hemmer S, Hillengass M, Goldschmidt H, Hartmann M, Schellberg D, Herzog W, Hillengass J.

BMJ Open. 2018 Jul 30;8(7):e021376. doi: 10.1136/bmjopen-2017-021376.

29.

Cardiovascular adverse events in modern myeloma therapy - Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA).

Bringhen S, Milan A, Ferri C, Wäsch R, Gay F, Larocca A, Salvini M, Terpos E, Goldschmidt H, Cavo M, Petrucci MT, Ludwig H, Auner HW, Caers J, Gramatzki M, Boccadoro M, Einsele H, Sonneveld P, Engelhardt M; European Hematology Association, the European Myeloma Network and the Italian Society of Arterial Hypertension.

Haematologica. 2018 Sep;103(9):1422-1432. doi: 10.3324/haematol.2018.191288. Epub 2018 Jul 26. Review.

30.

Cytogenetic abnormalities in monoclonal gammopathy of undetermined significance.

Merz M, Hielscher T, Hoffmann K, Seckinger A, Hose D, Raab MS, Hillengass J, Jauch A, Goldschmidt H.

Leukemia. 2018 Dec;32(12):2717-2719. doi: 10.1038/s41375-018-0202-1. Epub 2018 Jul 6. No abstract available.

PMID:
29977018
31.

A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis.

Walker BA, Mavrommatis K, Wardell CP, Ashby TC, Bauer M, Davies F, Rosenthal A, Wang H, Qu P, Hoering A, Samur M, Towfic F, Ortiz M, Flynt E, Yu Z, Yang Z, Rozelle D, Obenauer J, Trotter M, Auclair D, Keats J, Bolli N, Fulciniti M, Szalat R, Moreau P, Durie B, Stewart AK, Goldschmidt H, Raab MS, Einsele H, Sonneveld P, San Miguel J, Lonial S, Jackson GH, Anderson KC, Avet-Loiseau H, Munshi N, Thakurta A, Morgan G.

Leukemia. 2019 Jan;33(1):159-170. doi: 10.1038/s41375-018-0196-8. Epub 2018 Jul 2.

32.

Bortezomib-based induction therapy with high or low-dose dexamethasone in newly diagnosed, transplant-eligible multiple myeloma.

Mai EK, Hielscher T, Bertsch U, Schlenzka J, Salwender HJ, Munder M, Gerecke C, Dührsen U, Brossart P, Neben K, Hillengass J, Raab MS, Merz M, Baertsch MA, Jauch A, Hose D, Martin H, Lindemann HW, Blau IW, Scheid C, Weisel KC, Goldschmidt H; German-speaking Myeloma Multicenter Group (GMMG).

Leukemia. 2019 Jan;33(1):258-261. doi: 10.1038/s41375-018-0195-9. Epub 2018 Jun 29. No abstract available.

PMID:
29959413
33.

Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma.

Walker BA, Mavrommatis K, Wardell CP, Ashby TC, Bauer M, Davies FE, Rosenthal A, Wang H, Qu P, Hoering A, Samur M, Towfic F, Ortiz M, Flynt E, Yu Z, Yang Z, Rozelle D, Obenauer J, Trotter M, Auclair D, Keats J, Bolli N, Fulciniti M, Szalat R, Moreau P, Durie B, Stewart AK, Goldschmidt H, Raab MS, Einsele H, Sonneveld P, San Miguel J, Lonial S, Jackson GH, Anderson KC, Avet-Loiseau H, Munshi N, Thakurta A, Morgan GJ.

Blood. 2018 Aug 9;132(6):587-597. doi: 10.1182/blood-2018-03-840132. Epub 2018 Jun 8. Erratum in: Blood. 2018 Sep 27;132(13):1461.

34.

Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN).

Larocca A, Dold SM, Zweegman S, Terpos E, Wäsch R, D'Agostino M, Scheubeck S, Goldschmidt H, Gay F, Cavo M, Ludwig H, Straka C, Bringhen S, Auner HW, Caers J, Gramatzki M, Offidani M, Dimopoulos MA, Einsele H, Boccadoro M, Sonneveld P, Engelhardt M.

Leukemia. 2018 Aug;32(8):1697-1712. doi: 10.1038/s41375-018-0142-9. Epub 2018 Apr 25. Review.

35.

Going the distance: Are we losing patients along the multiple myeloma treatment pathway?

Terpos E, Suzan F, Goldschmidt H.

Crit Rev Oncol Hematol. 2018 Jun;126:19-23. doi: 10.1016/j.critrevonc.2018.03.021. Epub 2018 Mar 29. Review.

36.

Propensity score matching analysis to evaluate the comparative effectiveness of daratumumab versus real-world standard of care therapies for patients with heavily pretreated and refractory multiple myeloma.

Kumar S, Durie B, Nahi H, Vij R, Dimopoulos MA, Kastritis E, Terpos E, Leleu X, Beksac M, Goldschmidt H, Hillengass J, Su Z, Hutton B, Cameron C, Khan I, Lam A.

Leuk Lymphoma. 2019 Jan;60(1):163-171. doi: 10.1080/10428194.2018.1459609. Epub 2018 May 9.

PMID:
29741423
37.

Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network.

Ludwig H, Delforge M, Facon T, Einsele H, Gay F, Moreau P, Avet-Loiseau H, Boccadoro M, Hajek R, Mohty M, Cavo M, Dimopoulos MA, San-Miguel JF, Terpos E, Zweegman S, Garderet L, Mateos MV, Cook G, Leleu X, Goldschmidt H, Jackson G, Kaiser M, Weisel K, van de Donk NWCJ, Waage A, Beksac M, Mellqvist UH, Engelhardt M, Caers J, Driessen C, Bladé J, Sonneveld P.

Leukemia. 2018 Jul;32(7):1542-1560. doi: 10.1038/s41375-018-0040-1. Epub 2018 May 2. Review.

38.

[Long-term follow-up of monoclonal gammopathies of undetermined significance (MGUS)].

Goldschmidt H, Nitschmann S.

Internist (Berl). 2018 Jun;59(6):639-640. doi: 10.1007/s00108-018-0425-2. German. No abstract available.

PMID:
29696302
39.

The multiple myeloma risk allele at 5q15 lowers ELL2 expression and increases ribosomal gene expression.

Ali M, Ajore R, Wihlborg AK, Niroula A, Swaminathan B, Johnsson E, Stephens OW, Morgan G, Meissner T, Turesson I, Goldschmidt H, Mellqvist UH, Gullberg U, Hansson M, Hemminki K, Nahi H, Waage A, Weinhold N, Nilsson B.

Nat Commun. 2018 Apr 25;9(1):1649. doi: 10.1038/s41467-018-04082-2.

40.

Assessment of glucose metabolism and cellular proliferation in multiple myeloma: a first report on combined 18F-FDG and 18F-FLT PET/CT imaging.

Sachpekidis C, Goldschmidt H, Kopka K, Kopp-Schneider A, Dimitrakopoulou-Strauss A.

EJNMMI Res. 2018 Apr 10;8(1):28. doi: 10.1186/s13550-018-0383-7.

41.

Oncogene-induced senescence: a potential breakpoint mechanism against malignant transformation in plasma cell disorders.

Lehners N, Ellert E, Xu J, Hillengass J, Leichsenring J, Stenzinger A, Goldschmidt H, Andrulis M, Raab MS.

Leuk Lymphoma. 2018 Nov;59(11):2660-2669. doi: 10.1080/10428194.2018.1443450. Epub 2018 Apr 4.

PMID:
29616856
42.

Platelet Count before Peripheral Blood Stem Cell Mobilization Is Associated with the Need for Plerixafor But Not with the Collection Result.

Baertsch MA, Kriegsmann K, Pavel P, Bruckner T, Hundemer M, Kriegsmann M, Ho AD, Goldschmidt H, Wuchter P.

Transfus Med Hemother. 2018 Jan;45(1):24-31. doi: 10.1159/000478911. Epub 2017 Oct 4.

43.

Quantification of number of CD38 sites on bone marrow plasma cells in patients with light chain amyloidosis and smoldering multiple myeloma.

Kriegsmann K, Dittrich T, Neuber B, Awwad MHS, Hegenbart U, Goldschmidt H, Hillengass J, Hose D, Seckinger A, Müller-Tidow C, Ho AD, Schönland S, Hundemer M.

Cytometry B Clin Cytom. 2018 Sep;94(5):611-620. doi: 10.1002/cyto.b.21636. Epub 2018 Apr 20.

PMID:
29577600
44.

A systematic classification of death causes in multiple myeloma.

Mai EK, Haas EM, Lücke S, Löpprich M, Kunz C, Pritsch M, Knaup-Gregori P, Raab MS, Schlenzka J, Bertsch U, Hillengass J, Goldschmidt H.

Blood Cancer J. 2018 Mar 8;8(3):30. doi: 10.1038/s41408-018-0068-5. No abstract available.

45.

DNMTi/HDACi combined epigenetic targeted treatment induces reprogramming of myeloma cells in the direction of normal plasma cells.

Bruyer A, Maes K, Herviou L, Kassambara A, Seckinger A, Cartron G, Rème T, Robert N, Requirand G, Boireau S, Müller-Tidow C, Veyrune JL, Vincent L, Bouhya S, Goldschmidt H, Vanderkerken K, Hose D, Klein B, De Bruyne E, Moreaux J.

Br J Cancer. 2018 Apr;118(8):1062-1073. doi: 10.1038/s41416-018-0025-x. Epub 2018 Mar 2.

46.

Upregulation of FOXM1 in a subset of relapsed myeloma results in poor outcome.

Gu C, Holman C, Sompallae R, Jing X, Tomasson M, Hose D, Seckinger A, Zhan F, Tricot G, Goldschmidt H, Yang Y, Janz S.

Blood Cancer J. 2018 Feb 15;8(2):22. doi: 10.1038/s41408-018-0060-0. No abstract available.

47.

Carfilzomib in relapsed or refractory multiple myeloma patients with early or late relapse following prior therapy: A subgroup analysis of the randomized phase 3 ASPIRE and ENDEAVOR trials.

Mateos MV, Goldschmidt H, San-Miguel J, Mikhael J, DeCosta L, Zhou L, Obreja M, Blaedel J, Szabo Z, Leleu X.

Hematol Oncol. 2018 Apr;36(2):463-470. doi: 10.1002/hon.2499. Epub 2018 Feb 15.

PMID:
29446103
48.

Cytogenetic aberrations in multiple myeloma are associated with shifts in serum immunoglobulin isotypes distribution and levels.

Yadav P, Merz M, Mai EK, Försti A, Jauch A, Goldschmidt H, Hemminki K.

Haematologica. 2018 Apr;103(4):e162-e164. doi: 10.3324/haematol.2017.184226. Epub 2018 Feb 1. No abstract available.

49.

Outcome of a Salvage Third Autologous Stem Cell Transplantation in Multiple Myeloma.

Garderet L, Iacobelli S, Koster L, Goldschmidt H, Johansson JE, Bourhis JH, Krejci M, Leleu X, Potter M, Blaise D, Koenecke C, Peschel C, Radocha J, Metzner B, Lenain P, Schäfer-Eckart K, Pohlreich D, Grasso M, Caillot D, Einsele H, Ladetto M, Schönland S, Kröger N.

Biol Blood Marrow Transplant. 2018 Jul;24(7):1372-1378. doi: 10.1016/j.bbmt.2018.01.035. Epub 2018 Feb 3.

PMID:
29408334
50.

Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma.

Merz M, Jauch A, Hielscher T, Bochtler T, Schönland SO, Seckinger A, Hose D, Bertsch U, Neben K, Raab MS, Hillengass J, Salwender H, Blau IW, Lindemann HW, Schmidt-Wolf IGH, Scheid C, Haenel M, Weisel KC, Goldschmidt H.

Blood Adv. 2017 Dec 27;2(1):1-9. doi: 10.1182/bloodadvances.2017013334. eCollection 2018 Jan 9.

Supplemental Content

Loading ...
Support Center